missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Human Caspase 9 Synthetic Peptide

Numéro de catalogue. PEP0029
Modifier l'affichage
Click to view available options
Quantité:
50 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Numéro de catalogue. Quantité
PEP0029 50 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Numéro de catalogue. PEP0029 Fournisseur Invitrogen™ Code fournisseur PEP0029
Saison des économies
Afficher toutes les promotions

Pour de l'aide SVP utiliser la function de clavardage; nous envoyer un couriel à help@thermofisher.com ou appelez le service à la clientèle au 1-800-234-7437.

Synthetic Peptide

This peptide corresponds to 16 amino acids near the center of human Caspase-9. PEP-0029 can be used as a blocking peptide with polyclonal antibody PA5-19903.

Caspase 9 (ICE-like apoptotic protease 6, ICE LAP6, apoptotic protease Mch6, apoptotic protease activating factor 3, Apaf3) is a member of the peptidase family C14 that contains a CARD domain. Caspases are cysteine proteases, expressed as inactive precursors, that mediate apoptosis by proteolysis of specific substrates. Caspase 9 is active as a heterotetramer, is present in the cytosol and, upon activation, translocates to the mitochondria. Caspase 9 is involved in the caspase activation cascade responsible for apoptosis execution and cleaves/activates Caspase 3 and Caspase 6. Further, Caspase 9 is involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf- 1 leads to activation of the protease which then cleaves and activates caspase-3. Caspase 9 promotes DNA damage-induced apoptosis in a ABL1/c-Abl-dependent manner, and proteolytically cleaves poly(ADP- ribose) polymerase (PARP). Caspase 9 is expressed in variety of human tissues. An isoform of rat Caspase-9 has been identified in which the C terminus of full-length Caspase-9 is replaced with an alternative peptide sequence. Mutations in Caspase 9 affect brain development. In mice, insufficient Caspase 9 have resulted in abnormal cerebrum development and neuron development. In humans, dysfunctional Caspase 9 expression vary from tissue to tissue. Low levels of Caspase 9 may play a role in cancer development and neurodegenerative diseases such as Alzheimer's Disease (AD).

Spécifications

Espèces Human
Méthode de purification purified
Numéro d'enregistrement P55211
Nom usuel Caspase 9
Concentration 200 μg/mL
Format Liquid
Formule PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2
Alias du gène 25 kDa caspase-9 dominant negative protein; AI115399; APAF3; APAF-3; apoptotic protease activating factor 3; apoptotic protease MCH-6; Apoptotic protease-activating factor 3; AW493809; cas9; CASP 9; CASP9; CASP-9; Casp9_v1; Casp-9-CTD; caspase 9; caspase 9, apoptosis-related cysteine peptidase; caspase 9, apoptosis-related cysteine protease; Caspase9; caspase-9; caspase-9 dominant negative form; Caspase-9 precursor; Caspase-9 subunit p10; Caspase-9 subunit p35; CASPASE-9c; caspase-9-carboxyl-terminal divergent; CTD; Ice-Lap6; ICE-like apoptotic protease 6; Mch6; OTTHUMP00000002324; PPP1R56; protein phosphatase 1, regulatory subunit 56; RNCASP9; RP11-265F14.3
Symbole de gène CASP9
Lyophilisé No
Conservateur Sodium azide
Type de produit Peptide
Quantité 50 μg
Statut réglementaire RUO
Afficher plus de résultats Afficher moins de résultats